LPTX

Leap Therapeutics, Inc.

1.94 USD
+0.06 (+3.19%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Leap Therapeutics, Inc. stock is down -14.91% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 June’s closed higher than May.

About Leap Therapeutics, Inc.

Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.